Exploring Racial Disparities in Awareness and Perceptions of Oncology Clinical Trials: Cross-Sectional Analysis of Baseline Data From the mychoice Study.


Journal

JMIR cancer
ISSN: 2369-1999
Titre abrégé: JMIR Cancer
Pays: Canada
ID NLM: 101666844

Informations de publication

Date de publication:
30 Sep 2024
Historique:
received: 03 01 2024
accepted: 30 07 2024
revised: 28 04 2024
medline: 1 10 2024
pubmed: 1 10 2024
entrez: 30 9 2024
Statut: epublish

Résumé

Black/African American adults are underrepresented in oncology clinical trials in the United States, despite efforts at narrowing this disparity. This study aims to explore differences in how Black/African American oncology patients perceive clinical trials to improve support for the clinical trial participation decision-making process. As part of a larger randomized controlled trial, a total of 244 adult oncology patients receiving active treatment or follow-up care completed a cross-sectional baseline survey on sociodemographic characteristics, clinical trial knowledge, health literacy, perceptions of cancer clinical trials, patient activation, patient advocacy, health care self-efficacy, decisional conflict, and clinical trial intentions. Self-reported race was dichotomized into Black/African American and non-Black/African American. As appropriate, 2-tailed t tests and chi-square tests of independence were used to examine differences between groups. Black/African American participants had lower clinical trial knowledge (P=.006), lower health literacy (P<.001), and more medical mistrust (all P values <.05) than non-Black/African American participants. While intentions to participate in a clinical trial, if offered, did not vary between Black/African American and non-Black/African American participants, Black/African American participants indicated lower awareness of clinical trials, fewer benefits of clinical trials, and more uncertainty around clinical trial decision-making (all P values <.05). There were no differences for other variables. Despite no significant differences in intent to participate in a clinical trial if offered and high overall trust in individual health care providers among both groups, beliefs persist about barriers to and benefits of clinical trial participation among Black/African American patients. Findings highlight specific ways that education and resources about clinical trials could be tailored to better suit the informational and decision-making needs and preferences of Black/African American oncology patients.

Sections du résumé

BACKGROUND BACKGROUND
Black/African American adults are underrepresented in oncology clinical trials in the United States, despite efforts at narrowing this disparity.
OBJECTIVE OBJECTIVE
This study aims to explore differences in how Black/African American oncology patients perceive clinical trials to improve support for the clinical trial participation decision-making process.
METHODS METHODS
As part of a larger randomized controlled trial, a total of 244 adult oncology patients receiving active treatment or follow-up care completed a cross-sectional baseline survey on sociodemographic characteristics, clinical trial knowledge, health literacy, perceptions of cancer clinical trials, patient activation, patient advocacy, health care self-efficacy, decisional conflict, and clinical trial intentions. Self-reported race was dichotomized into Black/African American and non-Black/African American. As appropriate, 2-tailed t tests and chi-square tests of independence were used to examine differences between groups.
RESULTS RESULTS
Black/African American participants had lower clinical trial knowledge (P=.006), lower health literacy (P<.001), and more medical mistrust (all P values <.05) than non-Black/African American participants. While intentions to participate in a clinical trial, if offered, did not vary between Black/African American and non-Black/African American participants, Black/African American participants indicated lower awareness of clinical trials, fewer benefits of clinical trials, and more uncertainty around clinical trial decision-making (all P values <.05). There were no differences for other variables.
CONCLUSIONS CONCLUSIONS
Despite no significant differences in intent to participate in a clinical trial if offered and high overall trust in individual health care providers among both groups, beliefs persist about barriers to and benefits of clinical trial participation among Black/African American patients. Findings highlight specific ways that education and resources about clinical trials could be tailored to better suit the informational and decision-making needs and preferences of Black/African American oncology patients.

Identifiants

pubmed: 39348891
pii: v10i1e56048
doi: 10.2196/56048
doi:

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

e56048

Informations de copyright

©Ariel Hoadley, Linda Fleisher, Cassidy Kenny, Patrick JA Kelly, Xinrui Ma, Jingwei Wu, Carmen Guerra, Amy E Leader, Mohammed Alhajji, Paul D’Avanzo, Zoe Landau, Sarah Bauerle Bass. Originally published in JMIR Cancer (https://cancer.jmir.org), 30.09.2024.

Auteurs

Ariel Hoadley (A)

Department of Social and Behavioral Sciences, Temple University College of Public Health, Philadelphia, PA, United States.

Linda Fleisher (L)

Cancer Prevention and Control, Fox Chase Cancer Center, Philadelphia, PA, United States.

Cassidy Kenny (C)

Cancer Prevention and Control, Fox Chase Cancer Center, Philadelphia, PA, United States.

Patrick Ja Kelly (PJ)

Department of Social and Behavioral Sciences, Temple University College of Public Health, Philadelphia, PA, United States.

Xinrui Ma (X)

Department of Epidemiology and Biostatistics, Temple University College of Public Health, Philadelphia, PA, United States.

Jingwei Wu (J)

Department of Epidemiology and Biostatistics, Temple University College of Public Health, Philadelphia, PA, United States.

Carmen Guerra (C)

Abramson Cancer Center, University of Pennsylvania Medical Center, Philadelphia, PA, United States.

Amy E Leader (AE)

Division of Population Science, Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, United States.

Mohammed Alhajji (M)

Department of Social and Behavioral Sciences, Temple University College of Public Health, Philadelphia, PA, United States.

Paul D'Avanzo (P)

Department of Social and Behavioral Sciences, Temple University College of Public Health, Philadelphia, PA, United States.

Zoe Landau (Z)

Cancer Prevention and Control, Fox Chase Cancer Center, Philadelphia, PA, United States.

Sarah Bauerle Bass (SB)

Department of Social and Behavioral Sciences, Temple University College of Public Health, Philadelphia, PA, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH